Published in Lab Business Week, February 12th, 2006
Adlyfe's technology is significant in its potential impact in the early diagnosis and treatment of protein conformational animal and human diseases including Mad Cow Disease, Alzheimer and related wasting diseases.
Investors in the round include Canaan Partners and Burrill Associates. Seth Rudnick, from Canaan, and Ann Hanham, from Burrill, will join the Adlyfe board. "The diagnosis of misfolded proteins is a significant step on the road to both protecting populations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.